Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22

The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively

Biocon Q2FY22 in line with estimates, better margins: ICICI Direct

Key takeaways of recent quarter & conference call highlights

Gland Pharma PAT declines to Rs 302 crore QoQ in Q2FY22

The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand

Jubilant Pharmova consolidated PAT at Rs. 142.84 cr. in Q2FY22

The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment

Syngene revenue from operations up 17 per cent in Q2FY22

The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations

Expect normal quarter in Q2FY22: Emkay

Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct

The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct

Normalised quarter with impending margin pressure: ICICI Direct

ICICI Direct gives a preview on the earnings narrative for Q3FY22